GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers-Reference-Cited by-同舟云学术

GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers

Published:2018-10-31 Issue: Volume:8 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Lesueur Fabienne,Mebirouk Noura,Jiao Yue,Barjhoux Laure,Belotti Muriel,Laurent Maïté,Léone Mélanie,Houdayer Claude,Bressac-de Paillerets Brigitte,Vaur Dominique,Sobol Hagay,Noguès Catherine,Longy Michel,Mortemousque Isabelle,Fert-Ferrer Sandra,Mouret-Fourme Emmanuelle,Pujol Pascal,Venat-Bouvet Laurence,Bignon Yves-Jean,Leroux Dominique,Coupier Isabelle,Berthet Pascaline,Mari Véronique,Delnatte Capucine,Gesta Paul,Collonge-Rame Marie-Agnès,Giraud Sophie,Bonadona Valérie,Baurand Amandine,Faivre Laurence,Buecher Bruno,Lasset Christine,Gauthier-Villars Marion,Damiola Francesca,Mazoyer Sylvie,Caputo Sandrine M.,Andrieu Nadine,Stoppa-Lyonnet Dominique,

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference38 articles.

1. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families;Ford,1998

2. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2;Hopper,1999

3. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions;Antoniou

4. Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations;Brohet,2014

5. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers;Kuchenbaecker,2017

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease;European Journal of Cancer;2023-01

2. Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations;British Journal of Cancer;2022-10-07

3. Hereditary Breast and Ovarian Cancer;Obstetrics and Gynecology Clinics of North America;2022-03

4. Double heterozygous pathogenic variants in the BRCA1 and BRCA2 genes in a patient with bilateral metachronous breast cancer;Cancer Genetics;2022-01

5. Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach;The American Journal of Human Genetics;2021-10